Blood Test Guide

CD4 Count (T-Cell Count)

Name: CD4 Count: Normal Range & HIV Monitoring | HealthReview
Creator: Suman Konda
Published: 2026-07-05

CD4 count measures the immune cells HIV attacks. It tracks HIV disease progression and when to start treatment to protect against opportunistic infections.

Written and clinically reviewed by Suman Konda, PharmD, Clinical Pharmacist · Based on peer-reviewed sources · Editorial policy · Not medical advice

Last reviewed and updated: 01 August 2026 · How we check our content

CD4 count reference ranges

CD4 Count	Interpretation
500–1,500 cells/µL	Normal immune system
350–499 cells/µL	Mildly reduced: treatment recommended
200–349 cells/µL	Significantly reduced: high infection risk
<200 cells/µL	AIDS diagnosis: very high risk of opportunistic infections
<50 cells/µL	Severe AIDS: risk of CMV retinitis, MAC, cryptococcal meningitis

CD4 count and HIV treatment

When to start antiretroviral therapy (ART)

Current guidelines recommend starting ART for ALL people with HIV regardless of CD4 count: the earlier, the better. CD4 count is used to monitor immune recovery on treatment. With effective ART, CD4 counts typically rise by 50–150 cells/µL per year. The goal is to achieve a CD4 count above 500 cells/µL. People with CD4 <200 also need prophylaxis against Pneumocystis pneumonia (PCP) with trimethoprim-sulfamethoxazole.

CD4 count vs HIV viral load

Test	What it measures	Clinical use
CD4 count	Immune system strength	Monitors immune recovery, predicts infection risk
HIV viral load	Amount of HIV in blood	Monitors treatment effectiveness: goal is undetectable

What the Switching Trials Showed

Whether CD4 count is good enough to decide when treatment has failed was tested directly, and the answer is more interesting than a simple yes or no.

A randomised trial in Thailand followed 716 adults starting antiretroviral therapy, switching them to a second-line regimen either on CD4 criteria or on viral load. At three years the rate of clinical failure — death, a new AIDS-defining illness, or a CD4 below 50 — was 7.4% in the CD4 group and 8.0% in the viral load group. On that measure CD4 monitoring was not inferior.²

The difference was in what happened along the way. People monitored by CD4 switched a great deal later: a median of 24.7 months against 11.7 months. And they spent far longer with virus replicating before anyone acted — a median of 15.8 months of viraemia at the point of switching, against 7.2 months.² Clinical outcomes at three years looked similar; the time spent with uncontrolled virus did not.

The group CD4 monitoring missesCD4 can hold up while treatment is failing. In a study of patients with detectable virus, those carrying the M184V resistance mutation were less likely to meet immunological failure criteria than those without it — 34% against 45% — and their CD4 declined far more slowly.³ The people whose virus has become resistant are, on this measure, among the least likely to trigger a CD4-based alarm.

This is the practical reason viral load is the primary monitoring test wherever it is available, and CD4 has moved to a supporting role — assessing how much immune damage exists at diagnosis, deciding whether prophylaxis against opportunistic infections is needed, and tracking recovery. A stable CD4 is reassuring, but it is not evidence that treatment is working, because it can remain stable while it is not.

None of this makes CD4 obsolete. The trial authors framed their result as reassurance for programmes still relying on CD4 where viral load is not yet available.² Where both exist, viral load answers the question CD4 answers slowly.

Questions to ask your HIV doctor

What is my current CD4 count and is it rising on treatment?
Is my viral load undetectable?
Do I need prophylaxis against opportunistic infections?
How often should I have my CD4 and viral load checked?

Frequently Asked Questions

What does the CD4 count measure?

It measures the number of CD4 T-cells, a key type of immune cell. In people with HIV it shows how strong the immune system is and guides treatment and infection-risk decisions.

What is a normal CD4 count?

In healthy adults it's roughly 500–1,500 cells/µL. In HIV, a count below 200 indicates a higher risk of opportunistic infections and defines AIDS, prompting preventive treatment.

Does effective HIV treatment raise the CD4 count?

Yes. With effective antiretroviral therapy the CD4 count typically recovers over months to years, and the risk of infections falls substantially.

Why a single CD4 count can be misleading

CD4 counts fluctuate considerably in the same person from day to day and even within a day. Intercurrent infection, recent vaccination, corticosteroids, time of day and normal biological variation all shift the number, sometimes substantially. Treatment decisions are therefore based on trends across several measurements rather than any single value, and an unexpectedly low count in someone clinically well is usually repeated before anything changes.

The CD4 percentage is often more stable than the absolute count because it is less affected by swings in the total lymphocyte count. Where the two disagree, the percentage frequently gives the truer picture, and it is the preferred measure in young children, whose absolute counts are naturally much higher than adults'.

How monitoring has changed

The role of CD4 counting has narrowed. Because current guidance is to start antiretroviral therapy in everyone with HIV regardless of CD4 count, the count no longer decides when to begin treatment. Its remaining uses are assessing immune damage at diagnosis, deciding whether prophylaxis against opportunistic infections is needed and when it can stop, and confirming immune recovery. In someone stable on treatment with a suppressed viral load and a CD4 count comfortably above 350 cells/mm³, routine CD4 monitoring is often reduced or stopped, with viral load taking over as the main test.

Immunological non-response

A minority of people achieve full viral suppression but recover their CD4 count poorly or not at all. This is more likely in those who started treatment at a very low count, at older age, and with co-infections such as hepatitis C. It is not treatment failure in the virological sense, and the response is usually to continue effective therapy, address co-infections and modifiable factors, and maintain prophylaxis for longer rather than to change the regimen.

References

The clinical information on this page is drawn from peer-reviewed sources indexed by the US National Library of Medicine. Links go to the source so you can read it yourself.

HIV and AIDS. In: StatPearls. Treasure Island (FL): StatPearls Publishing. NCBI Bookshelf NBK534860
Jourdain G, Le Cœur S, Ngo-Giang-Huong N, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med. 2013;10(8):e1001494. PMID 23940461 · doi:10.1371/journal.pmed.1001494
Hoffmann CJ, Maritz J, van Zyl GU. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone. Trop Med Int Health. 2016;21(2):219–23. PMID 26584666 · doi:10.1111/tmi.12639